83417-25-8 Usage
General Description
5-(Pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine is a chemical compound with the formula C9H9N5. It is a member of the triazole family of compounds and contains a pyridine ring attached to the triazole ring. 5-(Pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine has potential applications in pharmaceutical research, as it can act as a ligand for metal complexes and has been studied for its potential biological activities. The presence of both a triazole and a pyridine moiety in its structure makes it an interesting molecule for drug design and development. Further research on its properties and potential applications may lead to its use in various fields such as medicine, agriculture, and material science.
Check Digit Verification of cas no
The CAS Registry Mumber 83417-25-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,3,4,1 and 7 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 83417-25:
(7*8)+(6*3)+(5*4)+(4*1)+(3*7)+(2*2)+(1*5)=128
128 % 10 = 8
So 83417-25-8 is a valid CAS Registry Number.
InChI:InChI=1/C8H9N5/c9-8-11-7(12-13-8)4-6-2-1-3-10-5-6/h1-3,5H,4H2,(H3,9,11,12,13)
83417-25-8Relevant articles and documents
Bioisosteric Design of Conformationally Restricted Pyridyltriazole Histamine H2-Receptor Antagonists
Lipinski, Christopher A.
, p. 1 - 6 (1983)
A process of bioisosteric drug design is described whereby, in a manner analogous to synthesis, key portions of an effector molecule are successively replaced by pharmacophores or bioisosteres.This process, when applied to histamine, leads to the competitive histamine H2-receptor antagonist prototype 3-amino-5-(2-amino-4-pyridyl)-1,2,4-triazole (7).The biaryl nature of 7 fixes internitrogen distances, and comparison of these with histamine suggests that 7 shares structural features more in common with histamine trans rather than histamine gauche conformations.Alkylation of the prototype pyridylamino group in 7 markedly improves both histamine H2-receptor antagonist and gastric acid antisecretory activity so that the resulting agent, 3-amino-5--1,2,4-triazole (8), is more active than cimetidine.
